New drug combo offers hope for elderly breast cancer patients avoiding surgery
NCT ID NCT02760030
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tested a combination of two hormone-based drugs (fulvestrant and palbociclib) in 14 older patients with hormone-sensitive breast cancer who could not have surgery or chose not to. The goal was to control the cancer and avoid the need for surgery. The treatment aims to block estrogen and slow tumor growth, offering a non-surgical option for frail patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IA BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Case Western University
Cleveland, Ohio, 44106, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017, United States
Conditions
Explore the condition pages connected to this study.